Long Term Sidus PMCF

Zimmer Biomet

Overview

The objectives of this study are to assess the safety and performance of the Sidus Stem-Free Shoulder Arthroplasty System in unilateral primary total shoulder arthroplasty.

The data collected from this study will serve the purpose of assessing safety and performance of the Sidus Shoulder. Safety: Will be assessed by monitoring the frequency and incidence of adverse events (AE), serious adverse events (SAE), and unanticipated adverse device effects (UADE). Performance: Will be determined by analyzing the implant survival, overall pain and functional performances (based on the ASES Patient Questionnaire and range of motion) and radiographic parameters of subjects who received the Sidus Shoulder. Implant survival will be based on removal or intended removal and determined using the observed component years (OCY) model as it is not anticipated that there will be adequate data at the 10 years follow-up to support Kaplan-Meier survivorship analysis. In the instance that there is sufficient data to perform Kaplan-Meier analysis, the analysis will be performed.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Osteoarthritis Post-traumatic; Arthrosis

Interventions

Sidus Stem-Free ShoulderDEVICE

Device: Sidus Stem-Free Total Shoulder Arthroplasty System

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patient must have previously participated in the Sidus IDE clinical trial. * Patient must not have undergone revision of the Sidus shoulder. * Patient must be able and willing to complete the protocol required follow-up. * Patient must be able and willing to sign the IRB/EC approved informed consent. Exclusion Criteria: * Patient is a prisoner. * Patient is a current alcohol or drug abuser. * Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions. * Patient did not previously participate in the Sidus IDE clinical trial. * Patient no longer has Sidus shoulder implanted.

Locations (7)

Norton Orthopaedic & Sports Medicine

Louisville, Kentucky, United States

MedStar Health

Baltimore, Maryland, United States

Rothman Institute

Philadelphia, Pennsylvania, United States

The Rothman Institute

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Safety: Monitoring frequency of AE, SAE and UADEs.

Will be assessed by monitoring the frequency and incidence of adverse events (AE), serious adverse events (SAE), and unanticipated adverse device effects (UADE).

Time frame: 10 Years

Performance: ASES Scores

Will be determined by analyzing the ASES Questionnaire in subjects who received the Sidus Shoulder. ASES consists of 3 subcomponent scores including pain, instability and activities of daily living. The pain score can be 0 to 10 with 0 being no pain and 10 being the worst pain imaginable. The instability score can be 0 to 10 with 0 being no instability and 10 being the worst instability imaginable. The activities of daily living consists of 10 questions with ordinal responses of 0, 1, 2, and 3. 3 involves no limitation and 0 is unable to do. The 3 subcomponents combine to make the overall ASES score which can range from 0 to 100 with 0 being the worst possible score and 100 being the best.

Time frame: 10 Years

Implant Survival

Based on removal or intended removal of the device and determined using the OCY or Kaplan-Meier method.

Time frame: 10 Years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.